Validation of [11C]ORM-13070 as a PET tracer for alpha2c-adrenoceptors in the human brain

Synapse

Volumn 69, Issue 3, 2015, Pages 172-181

  Lehto, Jussi ^a,b,c   Hirvonen, Mika M ^b   Johansson, Jarkko ^a   Kemppainen, Jukka ^a,c   Luoto, Pauliina ^a   Naukkarinen, Tarja ^d   Oikonen, Vesa ^a   Arponen, Eveliina ^a   Rouru, Juha ^d   Sallinen, Jukka ^d   Scheinin, Harry ^a   Vuorilehto, Lauri ^c   Finnema, Sjoerd J ^e   Halldin, Christer ^e   Rinne, Juha O ^a,b   Scheinin, Mika ^a,b,c  

^a UNIVERSITY OF TURKU   (Finland)

^b CRST Clinical Research Services Turku   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d ORION CORPORATION   (Finland)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alpha2 adrenoceptors; Atipamezole; Atomoxetine; Ketamine; Noradrenaline; PET

Indexed keywords

11C ORM 13070; ALPHA 1A ADRENERGIC RECEPTOR; ATIPAMEZOLE; ATOMOXETINE; CARBON 11; KETAMINE; NORADRENALIN; TRACER; UNCLASSIFIED DRUG; 1-(1-(2,3-DIHYDROBENZO(1,4)DIOXIN-2-YL)METHYL)-4-(3-METHOXYMETHYLPYRIDIN-2-YL)PIPERAZINE; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; DIOXANE DERIVATIVE; IMIDAZOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN BINDING; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; BRAIN; CAUDATE NUCLEUS; CENTRAL NERVOUS SYSTEM; CHEMICAL BINDING; COLD PRESSOR TEST; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; DRUG POTENCY; DRUG UPTAKE; EC50; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; METABOLISM; SCINTISCANNING; TISSUE DISTRIBUTION; VALIDATION STUDY;

ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; ADULT; BRAIN; DIOXANES; HUMANS; IMIDAZOLES; MALE; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOPHARMACEUTICALS; RECEPTORS, ADRENERGIC, ALPHA-2; TISSUE DISTRIBUTION;

EID: 84921347081     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21798     Document Type: Article

References (44)

1. Aalto S, Hirvonen J, Kajander J, Scheinin H, Nagren K, Vilkman H, Gustafsson L, Syvalahti E, Hietala J. 2002. Ketamine does not decrease striatal dopamine D2 receptor binding in man. Psychopharmacology (Berl) 164:401-406.
2. Arbeláez AM, Su Y, Thomas JB, Hauch AC, Hershey T, Ances BM. 2013. Comparison of regional cerebral blood flow responses to hypoglycemia using pulsed arterial spin labeling and positron emission tomography. PLoS One 8:e60085.
3. Arponen E, Helin S, Marjamaki P, Gronroos T, Holm P, Loyttyniemi E, Nagren K, Scheinin M, Haaparanta-Solin M, Sallinen J, Solin O. 2014. A PET tracer for brain alpha2C adrenoceptors, 11C-ORM-13070: Radiosynthesis and preclinical evaluation in rats and knockout mice. J Nucl Med 55:1171-1177.
4. Corman SL, Fedutes BA, Culley CM. 2004. Atomoxetine: The first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm 61:2391-2399.
5. DeFronzo RA, Tobin JD, Andres R. 1979. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223.
6. Fagerholm V, Rokka J, Nyman L, Sallinen J, Tiihonen J, Tupala E, Haaparanta M, Hietala J. 2008. Autoradiographic characterization of alpha(2C)-adrenoceptors in the human striatum. Synapse 62:508-515.
7. 11C]ORM-13070 - A PET study in the primate brain. Int J Neuropsychopharmacol. 2014 Dec 13. Epub ahead of print.
8. Grassi G, Esler M. 1999. How to assess sympathetic activity in humans. J Hypertens 17:719-734.
9. Hong IK, Chung ST, Kim HK, Kim YB, Son YD, Cho ZH. 2007. Ultra fast symmetry and SIMD-based projection-backprojection (SSP) algorithm for 3-D PET image reconstruction. IEEE Trans Med Imaging 26:789-803.
10. Hume SP, Hirani E, Opacka-Juffry J, Osman S, Myers R, Gunn RN, McCarron JA, Clark RD, Melichar J, Nutt DJ, Pike VW. 2000. Evaluation of [O-methyl-11C]RS-15385-197 as a positron emission tomography radioligand for central alpha2-adrenoceptors. Eur J Nucl Med 27:475-484.
11. Jakobsen S, Pedersen K, Smith DF, Jensen SB, Munk OL, Cumming P. 2006. Detection of alpha2-adrenergic receptors in brain of living pig with 11C-yohimbine. J Nucl Med 47:2008-2015.
12. Kalkman HO, Loetscher E. 2003. Alpha2C-adrenoceptor blockade by clozapine and other antipsychotic drugs. Eur J Pharmacol 462:33-40.
13. Karhuvaara S, Kallio A, Scheinin M, Anttila M, Salonen JS, Scheinin H. 1990. Pharmacological effects and pharmacokinetics of atipamezole, a novel alpha 2-adrenoceptor antagonist-A randomized, double-blind cross-over study in healthy male volunteers. Br J Clin Pharmacol 30:97-106.
14. Karhuvaara S, Kallio A, Salonen M, Tuominen J, Scheinin M. 1991. Rapid reversal of alpha 2-adrenoceptor agonist effects by atipamezole in human volunteers. Br J Clin Pharmacol 31:160-165.
15. Kawamura K, Akiyama M, Yui J, Yamasaki T, Hatori A, Kumata K, Wakizaka H, Takei M, Nengaki N, Yanamoto K, Fukumura T, Zhang MR. 2010. In vivo evaluation of limiting brain penetration of probes for alpha(2C)-adrenoceptor using small-animal positron emission tomography. ACS Chem Neurosci 1:520-528.
16. Kienbaum P, Heuter T, Michel MC, Peters J. 2000. Racemic ketamine decreases muscle sympathetic activity but maintains the neural response to hypotensive challenges in humans. Anesthesiology 92:94-101.
17. Lammertsma AA, Hume SP. 1996. Simplified reference tissue model for PET receptor studies. Neuroimage 4:153-158.
18. Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, Frackowiak RS. 1996. Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab 16:42-52.
19. Landau AM, Doudet DJ, Jakobsen S. 2012. Amphetamine challenge decreases yohimbine binding to alpha2 adrenoceptors in Landrace pig brain. Psychopharmacology (Berl) 222:155-163.
20. Laruelle M. 2000. Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review. J Cereb Blood Flow Metab 20:423-451.
21. Laurila JM, Xhaard H, Ruuskanen JO, Rantanen MJ, Karlsson HK, Johnson MS, Scheinin M. 2007. The second extracellular loop of alpha2A-adrenoceptors contributes to the binding of yohimbine analogues. Br J Pharmacol 151:1293-1304.
22. Lehto J, Virta JR, Oikonen V, Roivainen A, Luoto P, Arponen E, Helin S, Hietamaki J, Holopainen A, Kailajarvi M, Peltonen JM, Rouru J, Sallinen J, Virtanen K, Volanen I, Scheinin M, Rinne JO. 2015. Test-retest reliability of (11)C-ORM-13070 in PET imaging of alpha2C-adrenoceptors in vivo in the human brain. Eur J Nucl Med Mol Imaging 42:120-127.
23. Levitt DG. 2004. Physiologically based pharmacokinetic modeling of arterial-Antecubital vein concentration difference. BMC Clin Pharmacol 4:2.
24. Lorrain DS, Schaffhauser H, Campbell UC, Baccei CS, Correa LD, Rowe B, Rodriguez DE, Anderson JJ, Varney MA, Pinkerton AB, Vernier JM, Bristow LJ. 2003. Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge. Neuropsychopharmacology 28:1622-1632.
25. Luoto P, Suilamo S, Oikonen V, Arponen E, Helin S, Herttuainen J, Hietamaki J, Holopainen A, Kailajarvi M, Peltonen JM, Rouru J, Sallinen J, Scheinin M, Virta J, Virtanen K, Volanen I, Roivainen A, Rinne JO. 2014. (11)C-ORM-13070, a novel PET ligand for brain alpha2C-adrenoceptors: Radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men. Eur J Nucl Med Mol Imaging 41:1947-1956.
26. MacDonald E, Kobilka BK, Scheinin M. 1997. Gene targeting-homing in on alpha 2-adrenoceptor-subtype function. Trends Pharmacol Sci 18:211-219.
27. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, Huang Y, Simpson N, Ngo K, Van Heertum R, Laruelle M. 2001. Imaging human mesolimbic dopamine transmission with positron emission tomography. I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 21:1034-1057.
28. Montezinho LP, Miller S, Plath N, Jensen NH, Karlsson JJ, Witten L, Mork A. 2010. The effects of acute treatment with escitalopram on the different stages of contextual fear conditioning are reversed by atomoxetine. Psychopharmacology (Berl) 212:131-143.
29. Olli-Lähdesmäki T, Kallio J, Scheinin M. 1999. Receptor subtype-induced targeting and subtype-specific internalization of human alpha(2)-adrenoceptors in PC12 cells. J Neurosci 19:9281-9288.
30. Passchier J, Gee A, Willemsen A, Vaalburg W, van Waarde A. 2002. Measuring drug-related receptor occupancy with positron emission tomography. Methods 27:278-286.
31. Olli-Lähdesmäki T, Scheinin M, Pohjanoksa K, Kallio J. 2003. Agonist-dependent trafficking of alpha2-adrenoceptor subtypes: Dependence on receptor subtype and employed agonist. Eur J Cell Biol 82:231-239.
32. Rowland LM, Beason-Held L, Tamminga CA, Holcomb HH. 2010. The interactive effects of ketamine and nicotine on human cerebral blood flow. Psychopharmacology (Berl) 208:575-584.
33. Sallinen J, Hoglund I, Engstrom M, Lehtimaki J, Virtanen R, Sirvio J, Wurster S, Savola JM, Haapalinna A. 2007. Pharmacological characterization and CNS effects of a novel highly selective alpha2C-adrenoceptor antagonist JP-1302. Br J Pharmacol 150:391-402.
34. Sallinen J, Holappa J, Koivisto A, Kuokkanen K, Chapman H, Lehtimaki J, Piepponen P, Mijatovic J, Tanila H, Virtanen R, Sirvio J, Haapalinna A. 2013. Pharmacological characterisation of a structurally novel alpha2C-adrenoceptor antagonist ORM-10921 and its effects in neuropsychiatric models. Basic Clin Pharmacol Toxicol 113:239-249.
35. Santos MS, Moreno AJ, Carvalho AP. 1996. Relationships between ATP depletion, membrane potential, and the release of neurotransmitters in rat nerve terminals. An in vitro study under conditions that mimic anoxia, hypoglycemia, and ischemia. Stroke 27:941-950.
36. Sauer JM, Ring BJ, Witcher JW. 2005. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet 44:571-590.
37. Scheinin H, MacDonald E, Scheinin M. 1988. Behavioural and neurochemical effects of antipamezole, a novel alpha 2-adrenoceptor antagonist. Eur J Pharmacol 151:35-42.
38. Scheinin M, Lomasney JW, Hayden-Hixson DM, Schambra UB, Caron MG, Lefkowitz RJ, Fremeau RT Jr. 1994. Distribution of alpha 2-adrenergic receptor subtype gene expression in rat brain. Brain Res Mol Brain Res 21:133-149.
39. Scheinin H, Aantaa R, Anttila M, Hakola P, Helminen A, Karhuvaara S. 1998. Reversal of the sedative and sympatholytic effects of dexmedetomidine with a specific alpha2-adrenoceptor antagonist atipamezole: A pharmacodynamic and kinetic study in healthy volunteers. Anesthesiology 89:574-584.
40. Scheinin M, Sallinen J, Haapalinna A. 2001. Evaluation of the alpha2C-adrenoceptor as a neuropsychiatric drug target studies in transgenic mouse models. Life Sci 68:2277-2285.
41. Shiue C, Pleus RC, Shiue GG, Rysavy JA, Sunderland JJ, Cornish KG, Young SD, Bylund DB. 1998. Synthesis and biological evaluation of [11C]MK-912 as an alpha2-adrenergic receptor radioligand for PET studies. Nucl Med Biol 25:127-133.
42. Smith DF, Dyve S, Minuzzi L, Jakobsen S, Munk OL, Marthi K, Cumming P. 2006. Inhibition of [11C]mirtazapine binding by alpha2-adrenoceptor antagonists studied by positron emission tomography in living porcine brain. Synapse 59:463-471.
43. Tose R, Kushikata T, Yoshida H, Kudo M, Furukawa K, Ueno S, Hirota K. 2009. Orexin A decreases ketamine-induced anesthesia time in the rat: The relevance to brain noradrenergic neuronal activity. Anesth Analg 108:491-495.
44. Van der Mey M, Windhorst AD, Klok RP, Herscheid JD, Kennis LE, Bischoff F, Bakker M, Langlois X, Heylen L, Jurzak M, Leysen JE. 2006. Synthesis and biodistribution of [11C]R107474, a new radiolabeled alpha2-adrenoceptor antagonist. Bioorg Med Chem 14:4526-4534.